Neogen (NEOG) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Neogen (NEOG) over the past year, gaining 286.5% versus a gain of 101.2%. Over five years, ORKA leads with a +137.5% price change compared with -71.5% for NEOG. Oruka Therapeutics is the larger company by market cap ($5.12 billion vs $2.55 billion), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEOG | ORKA |
|---|---|---|
| Share price | $11.71 | $77.28 |
| Market cap | $2.55B | $5.12B |
| 1-day change | +0.26% | -2.79% |
| YTD return | +67.53% | +162.29% |
| 1-year return | +101.20% | +286.49% |
| 5-year return | -71.47% | +137.46% |
| Forward P/E | 30.82 | — |
| EPS (TTM) | $-0.26 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $870.40M | — |
| Revenue growth (YoY) | -2.72% | — |
| Net income (latest FY) | $-7.90M | $-105.43M |
| Gross margin | 46.93% | — |
| Operating margin | -2.48% | — |
| Net margin | -0.91% | — |
| 52-week high | $14.26 | $115.52 |
| 52-week low | $5.37 | $24.31 |
| Distance from 52-week high | -17.88% | -33.10% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.56% | +100.57% |
| Average volume | 3.14M | 896.59K |
| Shares outstanding | 218.11M | 66.21M |
| Employees | 2,636 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 2.0 times larger than Neogen by market value ($5.12B vs $2.55B).
- ORKA has outperformed NEOG by 185.3 percentage points over the past year.
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
NEOG vs ORKA FAQ
Which is bigger, Neogen or Oruka Therapeutics?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.12B compared with $2.55B for Neogen (NEOG).
Which stock has performed better over the past year, NEOG or ORKA?
ORKA returned +286.49% over the past 12 months, compared with +101.20% for NEOG (price return, excluding dividends). Past performance does not predict future results.
Are Neogen and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.